Depression Questionnaire was administered at baseline and follow up (when 322 men and 320 women were seen).

**Results:** The mean age of males and females was 64.3 years and 65.6 years respectively. Circulating 25(OH)D concentrations were lower in those attending clinic in summer/autumn compared to those attending in winter/spring (p < 0.001). 12.1% men and 17.2% women were vitamin D deficient (concentration <25 nmol/l) and 45.7% men and 47.0% women had concentrations between 40 and 75 nmol/l. We found no relationship between pain at baseline and circulating 25(OH)D concentration in either sex. Similarly there was no relationship between depression score and vitamin D status. However, women who had the highest circulating 25(OH)D concentrations (~75 nmol/l) had the highest risk of incident bodily pain (OR 6.31 CI 1.15, 34.7, p = 0.034) after adjustment for age, body mass index, season of baseline 25(OH)D and of 4-year assessment, social class, cigarette and alcohol consumption, history of osteoporosis, number of co-occurring diseases, physical activity, number of co-occurring diseases, daily pain and time in the sun. Using ordinal logistic regression analysis, the odds ratio of depression was 1.32 (95% CI 0.82, 2.12) for vitamin D deficient individuals compared to those with optimal 25(OH)D levels. Furthermore, a significant trend was observed for depression risk across quintiles of vitamin D concentration (p for trend = 0.001). The association was stronger for females than males (p for interaction = 0.031). There was no relationship observed between depression and 25(OH)D concentrations in those with past history of osteoporosis or current use of bone density medication. There was no relationship between 25(OH)D concentrations and depressive symptoms in males.

**Discussion:** Our results are consistent with existing literature suggesting that vitamin D deficiency is associated with increased risk of depression. It is possible that vitamin D deficiency may affect the brain through its influence on neurotransmitter production or metabolism. Further research is needed to determine the causality of this relationship. Vitamin D supplementation may be a potential intervention to reduce the risk of depression in populations with vitamin D deficiency. However, the study was limited by its cross-sectional design and the lack of information on interventions to treat vitamin D deficiency. Future studies are needed to confirm these findings and explore potential mechanisms underlying the relationship between vitamin D and depression.

**Disclosure statement:** A.G. has received research support from MSD and is the employer of Annie Gilbert. All other authors have declared no conflicts of interest.
calculate which risk factors were predictors for osteoporosis at hip and spine.

Methods: We measured BMD at hip and spine using a Hologic Discovery C scanner in 196 patients with RA who were over 50 or who had at least a 10 year history of the disease. We recorded the patients’ age, gender, disease duration, disease activity score in 28 joints (DAS28), ESR, presence of erosions, RF and CCP levels, together with all treatment including steroid dose and duration. We calculated the overall prevalence of osteoporosis and performed a multivariate analysis, assuming a linear model for continuous variables, to assess the factors predictive of reduced BMD in individuals.

Results: Osteoporosis (T score < −2.5) was present at either hip or spine in 61 RA patients (31%). Multivariate analysis showed that the predictors for decreased BMD at the spine were female gender and CCP positivity, while decreased BMD at the hip was associated with female gender, age and ESR. In addition, use of bisphosphonates was associated with lower BMD at both sites, as would be expected. We also noted a higher than expected number of patients with degenerative spinal disease which reduced the amount of reliable data available at this site.

Conclusions: Osteoporosis at hip and/or spine is common in patients with RA over 10 years duration. Bisphosphonate therapy appears to be appropriately targeted. However, there appear to be site specific risk factors remaining even after B cell return. Disease duration has been previously associated with peripheral bone loss; our present work suggests that disease severity is important in predicting spinal BMD whilst disease activity influences bone density at the hip. Females are at higher risk of osteoporosis at both these sites. Degenerative disease may be more common in RA and this needs to be considered when assessing bone density at this site.

Disclosure statement: The authors have declared no conflicts of interest.

136. BAFF BINDING RECEPTORS RELATED TO RELAPSE AFTER RTX IN PATIENTS WITH RHEUMATOID ARTHRITIS

Inmaculada de la Torre1,2, Rita A. Moura3, Maria Leandro3, Jonathan Edwards1 and Geraldine Cambridge1
1Rheumatology, University College London, London, United Kingdom; 2Rheumatology, Gregorio Maranon Hospital, Madrid, Spain; 3Rheumatology Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal

Background: Coordinated expression of BAFF binding receptors (BBRs) (BAFF-R, TACI, BCMA) control differentiation of B cells into immunoglobulin (Ig) secreting cells. We have reported that i) BAFF levels rise after B cell depletion with rituximab (RTX) in patients with RA, remaining raised even after B cell return ii) BAFF-R expression in naïve B cells (NB) and memory B cells (MB) is reduced after RTX and related to clinical relapse independently of serum BAFF levels or time to relapse after B cell return iii) Class-switch recombination (CSR) and autoantibody production is also related to clinical relapse after RTX. When B cells differentiate into Ig secreting cells, BAFF-R is lost and BCMA up-regulated. TACI is induced upon B cell activation, being present on most MB. Although expressed on <20% activated (CD6+IgM+NB, TACI is more related to CSR and plasma cell differentiation. BBR expression was therefore investigated in relation to clinical relapse in RA patients after RTX.

Methods: Phenotypic analysis of BAFF-R, TACI and BCMA expression on PBMC were performed using combinations of CD19, CD27, CD16, CD56 and Ig (% and mean fluorescence intensity-MFI) in normal controls (NC) (n = 5) and patients pre and after RTX, classified as concordant or discordant at relapse (C-R, n = 16), or discordant (relapsing > 3 months after repopulation; D-R, n = 10) or non-relapsing after B cell return (D-NR, n = 11).

Results: Mean % of NB cell BAFF-R+ was significantly lower only in patients relapsing (C-R: 65.3%, D-R: 89.7%) when compared to NC (%: p = 0.027, p = 0.029). Percentage and MFI of MB cell BAFF-R+ was significantly lower in all patients when compared to both NC and pre-RTX (%: p < 0.05, MFIp < 0.005). In patients relapsing, % NB cell TACI+ tended to be higher in C-R than D-R (23.4% vs 9.9%). All patients pre and after RTX had significantly lower % of TACI+ MB cells when compared to NC (%: p = 0.05). However % of MB cell TACI+ was significantly higher in D-NR when compared to D-R (p = 0.001), BAFF-R and BCMA did not always have an inverse correlation in plasma cell populations after RTX. Finally, C-R patients had higher % of plasma cells than D-R and D-NR (16.5% vs 2.06% and 1.85; p = 0.03 and p = 0.06).

Conclusions: Rises in autoantibody levels have been related to clinical relapse after RTX. Modulation of BBR expression permissive to plasma cell formation in C-R patients, associated with an earlier down regulation of BAFF-R and up regulation of TACI on (presumably activated autoreactive) NB cells may explain clinical relapse closer to B cell return. Normal BAFF-R expression on NB cells in D-NR patients may reduce the chance of becoming Ig producing cells, thereby lowering the chance of the autoreactive NB population differentiating into autoantibody producing cells. The consequences of disturbed BBR expression on B cell selection and the advancement or inhibition of progression to autoantibody production may help explain timing of relapse after RTX.

Disclosure statement: The authors have declared no conflicts of interest.

137. DYSREGULATED TOTAL SERUM IMMUNOGLOBULIN LEVELS IN PATIENTS WITH RA: RELATIONSHIPS WITH CLINICAL RESPONSE TO RITUXIMAB

Inmaculada de la Torre1,2, Maria Leandro3, Johnathan Edwards1 and Geraldine Cambridge1
1Rheumatology, University College London, London, United Kingdom; 2Rheumatology, Gregorio Maranon Hospital, Madrid, Spain

Background: In patients with RA treated with BCDT, IgA levels do not decrease to the same extent or in as many patients as IgM or IgG levels. Preliminary analysis of serum Ig levels in 131 patients in the UCL cohort of patients with RA showed that IgA levels were actually raised in 30 RA patients before treatment and did not always normalize following BCDT. IgM and IgG levels were raised in 29 and 16 patients respectively, normalizing in most after the first cycle of BCDT. In this prospective study we investigated whether levels of Ig isotypes at baseline were associated with clinical pattern of response.

Methods: 131 patients with RA treated with RTX were studied. Baseline serum Ig levels, CRP, DAS28, CD19+ve B cell count at baseline, 1, 3 and 5 months after first cycle of rituximab, were collected prospectively. Groups were defined related to baseline total Ig levels: Normal IgA (0.7-4.0 g/L), High IgA (>4.0 g/L), Normal IgG (7.0-16.0 g/L), High IgG (>16.0 g/L). Normal IgM (<2.3 g/L), High IgM (>2.3 g/L). Adequate depletion and B cell repopulation were defined as having <5 or ≤5 CD19+ cells/μL respectively. Mann Whitney U and Wilcoxon tests were performed for independent and paired parameters.

Results: All patients were adequately depleted at 1 month. Baseline CRP levels were significantly higher in the High IgA and IgG groups compared with those with normal baseline IgA (p = 0.0002; p = 0.03 respectively). Minimum CRP levels reached in all groups were significantly lower compared to pre-RTX levels (p = 0.0001) but patients starting with High IgA had a significantly higher minimum CRP (p = 0.002) and also remained with higher minimum DAS28 when compared to those starting with Normal IgA (p = 0.05). After 5 months, patients in the High IgA group had significantly more CD19+ cells (p = 0.003) than those with normal baseline IgA and the proportion of patients repopulating at 5 months was also significantly greater in the High IgA group (**p = 0.004, Fisher’s exact test) (Table 1). Baseline levels of IgM were not correlated with any parameters evaluated.

Conclusions: Baseline levels of Ig may be predictive of the pattern of clinical response to rituximab. Patients with initially higher total serum IgA and IgG had significantly higher levels of baseline CRP and those in the High baseline IgA group had higher minimum DAS28 scores after rituximab than those with Normal baseline IgA. In addition, a larger proportion of patients with higher baseline IgA were more likely to have detectable B cells at 3 and 5 months and also had significantly higher numbers of repopulating B cells at five months post rituximab despite significant depletion.

Disclosure statement: The authors have declared no conflicts of interest.

Table 1.

<table>
<thead>
<tr>
<th>Ig Group</th>
<th>Number and % patients with CD19+ cells &gt; 5/μL</th>
<th>Number and % patients with CD19+ cells &gt; 5/μL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>with CD19+ cells &gt; 5/μL 3 months after RTX</td>
<td>5 months after RTX</td>
</tr>
<tr>
<td>High IgA</td>
<td>9/26 (34.6)</td>
<td>15/23 (65.2)**</td>
</tr>
<tr>
<td>Normal IgA</td>
<td>6/44 (13.6)</td>
<td>13/49 (26.5)</td>
</tr>
<tr>
<td>High IgG</td>
<td>4/20 (20.0)</td>
<td>10/17 (58.8)</td>
</tr>
<tr>
<td>Normal IgG</td>
<td>8/40 (20.0)</td>
<td>15/44 (34.1)</td>
</tr>
</tbody>
</table>

**p = 0.004, Fisher’s exact test
138. ASSESSMENT OF SYNOVITIS IN RHEUMATOID ARTHRITIS AND THE EFFECT OF ULTRASOUND JOINT COUNTS ON DAS28 VALUES
Louise E. Daniels1, Nicola J. Gullick1,2, Jonathan D. Rees1,3 and Bruce W. Kirkham1,2
1RA Centre, Rheumatology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom; 2NIHR Comprehensive Biomedical Research Centre, Guy's & St Thomas' Hospitals & King's College London, London, United Kingdom; 3Rheumatology, DMRG Headley Court, Surrey, United Kingdom

Background: The DAS28 is a composite measure of disease activity in patients with Rheumatoid Arthritis (RA). Patients with a moderate DAS 28 (3.2-5.1) have ongoing loss of function and continued joint damage. Current UK treatment guidelines require DAS 28 > 5.1 to qualify for anti-TNF therapy. Ultrasound (US) assessment of joint swelling is more sensitive than clinical examination, and clinical joint counts may have moderate interobserver variability. We conducted a study to investigate patients for subclinical synovitis and evaluate effects on DAS28 scores and potential treatment options.

Methods: 20 patients with RA had 28 joint counts performed by a consultant and a trainee rheumatologist. 10 MCP and PIP joints (total 400 joints) were scanned in two planes with grey scale and power Doppler US by an independent assessor. Agreement between clinical examinations and US was assessed by intra-class correlation coefficients (ICC) and percentage absolute agreement. DAS28 scores were calculated using both standard joint counts, then substituting the US swollen joint count or Doppler count for clinical swollen (SJC) or tender joint counts (TJC).

Results: ICC for SJC and TJC were 0.50 and 0.90, with high agreement of DAS28 scores (ICC 0.93) between the two observers. Exact agreement was seen in 187/240 (78%) for swelling and 201/240 (84%) for tenderness. US detected more synovitis and joint effusion (349/380 (91%), compared to clinical swelling (87/240 (36%), 23%) (p < 0.001). It also detected more vascularity on PD (224/380 joints, 59%), compared to clinical tenderness (94/380 joints, 24%) (p < 0.001). There were no significant correlations between clinical and US scores. The mean DAS 28 based on clinical scores was 4.1 (SD 1.3). This increased to 4.9 (SD 1.3) (p < 0.001) when US swelling was substituted for SJC. The mean DAS 28 increased further and significantly to 5.7 (SD 0.8) (< 0.001) when US vascularity was also substituted for TJC.

Conclusions: The consultant detected significantly more swelling than the trainee, but this had little effect on the DAS 28, due to a low weighting of swelling in the score. US detected significantly more synovitis and substitution of US derived counts had a significant effect on the DAS28. Four additional patients (29%) had a DAS28 > 5.1 based on US swelling assessments, and an additional 9 patients had a DAS28 > 5.1 if the Doppler count was additionally substituted for the clinical tender joint count. We suggest that a large number of RA patients with moderate DAS 28 scores have significant ongoing disease activity. This supports the recent BSR guidance that patients with moderate disease activity. This supports the recent BSR guidance that biologic therapies should be available to patients with moderate disease activity. This supports the recent BSR guidance that biologic therapies should be available to patients with moderate DAS 28 scores and an additional 9 patients had a DAS28 > 5.1 if the Doppler count was additionally substituted for the clinical tender joint count. We suggest that a large number of RA patients with moderate DAS 28 scores have significant ongoing disease activity. This supports the recent BSR guidance that patients with moderate disease activity. This supports the recent BSR guidance that biologic therapies should be available to patients with moderate disease activity. This supports the recent BSR guidance that patients with moderate disease activity. This supports the recent BSR guidance that biologic therapies should be available to patients with moderate disease activity.

Disclosu re statement: B.K. has served on advisory boards for and received research support from Bristol-Myers Squibb, Pfizer, Abbott, Centocor, Roche and UCB. All other authors have declared no conflicts of interest.

| Table 1. Effects of US joint counts on DAS28 scores |
|-------------------|-----|-----|-----|-----|
|                   | 2-6 | 7-3.1 | 3.2-5.1 | >5.1 |
| DAS28 (SJC)        |      |      |      |      |
| DAS2 (TJC)         | 1   | 0   | 10   | 4    |
| DAS2 (SJC)         | 0   | 0   | 6    | 13   |

139. A COMPARISON OF 3D AND 2D ULTRASOUND IN THE DETECTION OF SYNOVITIS, EROSIONS AND POWER DOPPLER ACTIVITY IN RHEUMATOID ARTHRITIS
Louise E. Daniels1, Nicola J. Gullick1, Bruce W. Kirkham1 and Jonathan Rees1
1Department of Rheumatology, Guy's and St Thomas' Hospitals, London, United Kingdom; 2Rheumatology, DMRG Headley Court, Surrey, United Kingdom

Background: Rheumatoid Arthritis (RA) is a common chronic, symmetrical inflammatory polyarthritis characterised by joint swelling resulting in damage and reduced physical function. Two-dimensional (2D) Ultrasound (US) is a highly sensitive and specific tool which has greatly assisted the diagnosis and determination of clinical activity and structural damage in RA. 3D US is an emerging imaging modality that has yet to be studied systematically in relation to arthritis of small joints in RA. We wanted to determine the utility of 3-D US in comparison to 2-D US in established RA patients in terms of assessment of synovitis and structural damage.

Methods: 20 patients with a diagnosis of RA were recruited. All 10 MCP and 10 PIP joints were scanned with a 2D and 3D probe. This gave a total of 400 joints in the 20 patients. Images were scored using standard semi-quantitative systems for three criteria; synovitis and joint effusion, power Doppler (PD) and erosions.

Results: Erosions were detected in 70% of joints with 3D US compared to 47% with 2D US (p = 0.009). Furthermore 3D US demonstrated greater severity of erosions than was demonstrated in 2D US. 3D US detected synovitis and joint erosions in 96% of joints compared with 91% with 2D US (p = 0.048). It was not possible to accurately detect synovial vascularity using 3D PDUS due to movement artefact from the 3D probe.

Conclusions: 3D US is more sensitive than 2D US for the detection of synovitis, joint erosions and erosions than 2D US. 3D US may have a role in confirming disease activity and structural damage in RA over and above that of 2D US. Further work is required to optimise the PD feature of 3D US.

Disclosure statement: B.K. has served on advisory boards for and received research support from Bristol-Myers Squibb, Pfizer, Abbott, Centocor, Roche and UCB. All other authors have declared no conflicts of interest.

140. CARDIOVASCULAR DISEASE IN RHEUMATOID ARTHRITIS IS PREDOMINANTLY DRIVEN BY TRADITIONAL CARDIOVASCULAR RISK FACTORS
Ian C. Scott1, Deborah Johnson2, David L. Scott3 and Gabrielle Kingsley1
1Rheumatology, Guy's and St Thomas' NHS Trust, London, United Kingdom; 2Rheumatology, University Hospital of Lewisham, London, United Kingdom; 3Rheumatology, King's College Hospital, London, United Kingdom

Background: The excessive cardiovascular (CV) risk in rheumatoid arthritis (RA) is well known. It reflects both the effects of traditional CV risk factors and systemic inflammation in RA. Currently rheumatologists mainly focus on reducing systemic inflammation in RA, which is known to reduce atherosclerosis. Although reducing conventional CV risk factors may be equally important they are not always assessed by rheumatologists. We therefore evaluated the overall management of CV risk factors in RA patients and examined the relative contribution of conventional CV risk factors to CV morbidity.

Methods: We cross-sectionally studied 305 RA patients attending specialist clinics in South East London. We assessed RA characteristics, screening/treatment of CV risk factors (hypertension, hyperlipidaemia, diabetes, obesity, smoking) and RA/CV treatments. Atherosclerosis was defined as a previous CV event. Factors associated with atherosclerosis were evaluated using binary logistic regression.

Results: The patients comprised 81% females of median age 60 years and median disease duration 8 years. Disease activity was moderate (mean DAS28 3.45). 28 (9%) had a previous CV event. CV risk factors were common; hypertension (57%), hyperlipidaemia (30%), diabetes (11%), ex/current smokers (52%) and obesity (31%). Screening for risk factors was inadequate: only one third of patients without known diabetes or hyperlipidaemia had ever had fasting glucose or lipid levels performed. CV risk factors were undertreated; 52% of patients on anti-hypertensives had ongoing hypertension. Hyperlipidaemia and hypertension were significantly associated with atherosclerosis (OR 1.01). Indirect markers of long-term inflammation - disease duration and erosions - were associated with atherosclerosis to a lesser extent. Hypertension (OR 4.3, 95%CI 1.1-16.8) and disease duration (OR 1.1, 95%CI 1.0-1.1) retained their significance in a multivariate model that did not include hyperlipidaemia (as statin use in ACR guidelines are known to reduce atherosclerosis). Although reducing conventional CV risk factors may be equally important they are not always assessed by rheumatologists. We therefore evaluated the overall management of CV risk factors in RA patients and examined the relative contribution of conventional CV risk factors to CV morbidity.

Conclusions: Although chronic inflammation contributes to atherosclerosis in RA, hyperlipidaemia and hypertension are dominant factors. Despite this association CV risk factors were insufficiently screened for and under treated in this population. We recommend rheumatologists should take responsibility for CV risk factor assessment. Once identified they can be treated in primary care.

Disclosure statement: The authors have declared no conflicts of interest.
141. PERSISTING REMISSION IS ESSENTIAL TO ACHIEVE LOW HAQ SCORES IN RHEUMATOID ARTHRITIS

Margaret H. Ma1, Andrew P. Cope2, David L. Scott1 and Bruce W. Kirkham2
1Rheumatology, King’s College Hospital, London, United Kingdom; 2Rheumatology, Guy’s and St Thomas’ Hospital, London, United Kingdom

Background: Remission has become the treatment target in RA. Goal directed therapy (GDT) targeting remission has the propensity to reduce disability and minimise radiographic progression. However, the relative benefits of sustained over intermittent remission are uncertain. There is also limited data about those patients most likely to achieve sustained remission. We addressed both these questions using real life data collected in a clinical practice setting.

Methods: We examined the frequency, predictors and impact of remission in prospectively collected routine practice data. The dataset comprised of demographics descriptors, disability (HAQ), disease activity (DAS28), C-reactive protein (CRP) and Rheumatoid Factor. DAS28<2.6 was used as the definition of remission. Sustained remission is defined as persistent remission over 4 consecutive visits. One-way ANOVA analysis and Spearman’s correlation were used to assess the relationship of HAQ and disease activity and logistic regression analysis was used to evaluate the predictors of sustained remission.

Results: We studied 316 RA patients followed over 4 consecutive visits. 249 (79%) were female and their mean age was 56 years (SD 14). 174 patients (55%) were rheumatoid factor positive, 32 patients (10%) had nodules and 133 patients (42%) had erosions on plain film x-rays. 45% of patients achieved remission at some point during the follow-up period; 57% (18%) of patients were in remission at 1 time point (point remission), 54 (17%) were in remission over 2-3 time points (intermittent remission) and 31 (10%) of patients were in sustained remission. Average HAQ and average DAS across the 4 visits were highly correlated (Spearman’s R = 0.54) with no evidence of a floor effect. Patients in remission achieved lower HAQ scores than patients with active disease and this effect was greater with increasing length of remission. Patients in sustained remission achieved the lowest HAQ scores (Table 1). This effect was persistent over time. Multivariate logistic regression showed initial tender joint counts (OR 0.51, 95% CI 0.29 - 0.93) and ESR (OR 0.81, 95% CI 0.70 - 0.93) were the key predictors of sustained remission.

Conclusions: Despite using GDT approach, only 10% of patients achieved sustained remission. This was predicted by initial tender joint count and ESR. Low HAQ scores are associated with remission, but sustained remission is vital to minimise HAQ. As sustained remission should be the ultimate treatment goal, the ideal treatment regimen still needs to be determined.

Disclosure statement: The authors have declared no conflicts of interest.

Table 1. Relationship between remission and HAQ over the consecutive visits.

<table>
<thead>
<tr>
<th>Visit</th>
<th>Mean HAQ (S.D.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.53 (0.20)</td>
</tr>
<tr>
<td>2</td>
<td>0.48 (0.18)</td>
</tr>
<tr>
<td>3</td>
<td>0.45 (0.15)</td>
</tr>
<tr>
<td>4</td>
<td>0.42 (0.13)</td>
</tr>
</tbody>
</table>

142. DO WE NEED SAME-DAY ESR FOR DAS-28 MEASUREMENT?
Sven Brode1, Muhammad K. Nisar2 and Andrew J. Östör2
1School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom; 2Rheumatology Clinical Research Unit, Addenbrooke’s Hospital, Cambridge, United Kingdom

Background: The Disease Activity Score (DAS-28) is the most widely used composite index of disease activity in Rheumatoid Arthritis (RA). The components include the number of swollen and tender joints, erythrocyte sedimentation rate (ESR) and visual analogue scale (VAS). Serial measurements of the DAS-28 are strong predictors of physical disability and radiological progression, and can sensitively discriminate between high and low disease activity. National Institute of Health and Clinical Excellence recommends the use of DAS-28 to initiate and monitor biologic therapy for RA. In clinical practice, rheumatologists have been reluctant to calculate the DAS-28 without a same-day ESR leading to unnecessary delay in adjusting targeted therapy. The aim of this prospective study was to assess whether ESR blood samples taken prior to the clinic appointment were adequate to accurately assess disease activity using DAS-28.

Methods: Patients with RA (N = 130) attending rheumatology outpatient clinics at Addenbrooke’s Hospital were selected and assessed at baseline. Seventy three participants, mean age 61.8 years (range 20-85 yr) and disease duration of 12.0 years (range 0.1-40 yr) completed the study. The tender and swollen joints were counted and the global disease activity was assessed using a VAS. Blood samples were collected for the ESR on the day of the appointment. ESR results up to six months prior were obtained and used for comparison.

Results: Comparing the same-day ESR versus pre-recorded ESR (range 6-190 days, mean interval = 47 days) showed a statistically significantly reduction in the same day ESR (K = 0.88 mm, 95% CI 0.79-0.97, log 10.7 mm, student t test, p = 0.01). However, this small difference in ESR did not significantly alter the DAS-28 score which remained strongly linearly correlated. Changes in the ESR were not significantly associated with the other clinical parameters used in the DAS-28 score (p = 0.157). In addition, any differences between ESR pairs were not correlated with the overall DAS-28 score. Time-dependent comparison over a six month period showed a difference in DAS-28 of less than ± 0.6 using even up to three months old ESR results.

Conclusions: Our results indicate that in clinical practice changes in DAS-28 due to an “out-of-date” ESR are minimal. The difference in ESR values over a period of up to three months have no clinically significant contribution to variations in DAS-28, especially in the absence of any preceding changes in RA management. A decision to adjust treatment may therefore be confidently made using latest ESR for calculating DAS-28 even if ESR sample was not acquired during clinical appointment.

Disclosure statement: The authors have declared no conflicts of interest.

143. ACHIEVING REMISSION DURING GOAL DIRECTED THERAPY IMPROVES FUNCTIONAL OUTCOME OF RA IN ROUTINE PRACTICE
Nicola J. Gullick1,2, Stephen P. Oakley1,3, Jonathan D. Rees1,4, Tim Jones1,4, Alan Mistlin1,4, Gabriel S. Panayi1,2 and Bruce W. Kirkham1,2
1RA Centre, Rheumatology, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom; 2NHRI comprehensive Biomedical Research Centre, Guy’s & St Thomas’ Hospitals & King’s College London, London, United Kingdom; 3Rheumatology, Royal Newcastle Centre, Newcastle, NSW, Australia; 4Rheumatology, DMRC Headley Court, Surrey, United Kingdom

Background: Recent EULAR guidelines recommend that RA patients should be treated to a target of remission, but there is little data from routine practice to suggest that this benefits patients. The RA Centre at Guy’s & St Thomas’ has used this strategy aiming for DAS28 remission for all patients with RA since 2005.

Methods: We performed a longitudinal cohort study involving all patients attending the RA Centre. DAS28 and HAQ are collected at each visit. Baseline and follow up at years 1, 2 and 3 have been included in this analysis. All eligible patients were included in the analysis. Comparisons were made between yearly timepoints. P values less than 0.05 were considered statistically significant.

Results: 3 year follow up data were available for 281 patients, with baseline visits occurring between 2005 and 2007. A variety of therapies were used, with increasing numbers of patients receiving biologic therapies during the follow up period, and reduced systemic
steroids. Increasing numbers of patients achieved remission or low disease activity during follow up with statistically significant improvements in DAS28 at all time points vs. baseline (Table 1). For the whole group there was no significant change in HAQ. Of the 228 patients with active disease (DAS28 > 2.6) at baseline, 119 achieved remission at least once during follow up. These patients had a small but significant improvement in HAQ from baseline to year 3 (median 1.25 vs. 1.0 p = 0.001). Patients in remission at baseline generally remained in remission and had stable lower HAQ values over three years.

Conclusions: Routine use of the DAS28 to guide changes in therapy improves disease activity and maintains functional capacity in an unselected group of patients with established RA. In addition, patients who achieve remission for even short periods had improved function.

This data supports the use of a goal directed strategy with a target of DAS28 remission for patients with established RA in routine practice. Achieving low DAS28 states is a relevant goal to prevent functional decline. We suggest that increasing loss of function is another significant adverse outcome of patients with even moderate disease activity, and supports the use of more aggressive therapy in this group.

Disclosure statement: B.K. has served on advisory boards for Pfizer, Bristol-Myers Squibb, Centocor, Roche, UCB and Abbott, and has received research grants from Pfizer, Centocor and Abbott. S.O. has received a research grant from Sanofi-Aventis. All other authors have declared no conflicts of interest.

144. INFILXIMAB INFUSION THERAPY IN INFAMMATORY ARTHRITIS: ASSESSMENT OF THE ACCELERATED INFUSION PROTOCOL IN COMPARISON TO THE STANDARD INFUSION APPROACH

Yasser El Miedy1 and Deborah Palmer1
1Rheumatology, Darent Valley Hospital, Dartford, United Kingdom

Background: Objectives: To assess the safety and prevalence of infusion reactions in patients suffering from inflammatory arthritis receiving infliximab via an accelerated infusion protocol in comparison to the standard infliximab infusions (over 2-hour period). Also to determine the prevalence of infusion related reactions in patients suffering from inflammatory arthritis receiving infliximab via an accelerated infusion protocol in comparison to none in the second group (p < 0.001). In the accelerated infusion protocol (first four infusions over 2 h, with 2 h of monitoring, the next five infusions over 1 h, and subsequent infusions over 30-60 min) in comparison to the standard infliximab infusions administered over minimum of 2 hours and patients are monitored for a further 2 hours.

Table 1. Follow-up clinical data

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAS28, median (IQR)</td>
<td>64 (22.8)</td>
<td>82 (29.25)</td>
<td>89 (31.75)</td>
<td>90 (32.3)</td>
</tr>
<tr>
<td>LDAS n (%)</td>
<td>35 (12.5)</td>
<td>51 (18.1)</td>
<td>50 (17.8)</td>
<td>55 (19.6)</td>
</tr>
<tr>
<td>low MDAS n (%)</td>
<td>47 (16.7)</td>
<td>56 (19.9)</td>
<td>40 (12.3)</td>
<td>43 (15.3)</td>
</tr>
<tr>
<td>high MDAS n (%)</td>
<td>77 (27.4)</td>
<td>50 (17.8)</td>
<td>47 (16.7)</td>
<td>46 (16.4)</td>
</tr>
<tr>
<td>HAQ, median (IQR)</td>
<td>85 (20.3)</td>
<td>47 (16.7)</td>
<td>40 (13.9)</td>
<td>43 (15.3)</td>
</tr>
<tr>
<td>Patient global score, mean (s.c.)</td>
<td>41.8 (27.4)</td>
<td>39.4 (27.3)</td>
<td>36.1 (25.3)</td>
<td>36.8 (25.4)</td>
</tr>
<tr>
<td>Pain VAS, mean (s.c.)</td>
<td>40.6 (27.9)</td>
<td>38.5 (27.4)</td>
<td>36.3 (24.6)</td>
<td>38.6 (26.3)</td>
</tr>
<tr>
<td>ESR, mean (s.c.)</td>
<td>25.6 (21.8)</td>
<td>24.2 (19.6)</td>
<td>22.0 (18.6)</td>
<td>19.8 (16.7)</td>
</tr>
<tr>
<td>p &lt; 0.005, 1 p &lt; 0.01, 2 p &lt; 0.0001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

146. THE SWINDON RA FOOT AND ANKLE QUESTIONNAIRE: IS A PICTURE WORTH A THOUSAND WORDS?

Rosemary Waller1, Lynn Williamson1, David Collins1, Elizabeth Price1 and Maria J. Juarez1
1Rheumatology, Great Western Hospital, Swindon, United Kingdom

Background: Despite increased awareness of the high prevalence and significance of foot and ankle problems in Rheumatoid Arthritis (RA), feet remain a neglected area and provision of care a ‘Cinderella’
service in many NHS Trusts. Reasons may include the perception that feet are difficult to assess and foot and ankle is not included in the standard DAS28 score. Currently available tools screening for foot problems are either not freely available, not specific for RA or are lengthy to complete.

Methods: We designed a short, simply worded questionnaire to screen for foot and ankle problems in rheumatology outpatients. Key features are 10 short questions on 1 side of A4 covering the domains of symptoms, function, disability and previous interventions. The unique feature of the questionnaire is the inclusion of pictures of dorsal, planar and lateral views of both feet. The questionnaire was piloted and modified after an anonymous survey of 448 patients at our institution in December 2009. All RA patients on our database were sent the questionnaire and invited to attend clinic for a detailed foot and ankle assessment. Each question was answered yes or no: yes score 1; no score 0; maximum score 10. Patients assessed in clinic were scored out of 10 using the same parameters as the questionnaire. The picture was reviewed at the end of the consultation and scored as ‘accurate’, ‘not accurate’ or ‘not completed’. Any intervention (including injection, orthotics or surgical review) arranged as a result of the clinic was documented.

Results: 597 questionnaires were sent, 301 returned and 137 patients were seen in clinic; 69% female; median age 62; mean RA duration 14 years (range 1 - 40 years). There was good correlation between the postal questionnaire score, the score assigned at clinic (r = 0.63) and the Manchester foot score (MFS) (r = 0.65). Neither score correlated with other disease outcome measures used to assess RA, including DAS28, Patient Health Assessment Questionnaire, Overall Status in Rheumatoid Arthritis & Hospital Anxiety & Depression scores.

96 (75%) patients completed the picture. Those who did had higher scores and 73% corresponded well to clinical findings. 124 (91%) patients had at least one foot or ankle problem: MTP synovitis (17%); peroneal and tibialis posterior tendinopathies (22%); halux valgus (38%) and callosities (18%) were the most common. 45% of patients received an intervention as a result of their clinic review. Those requiring intervention had a trend towards a higher score.

Conclusions: The Swindon RA Foot and Ankle Questionnaire was quick to complete, did not add to consultation length and correlated well with the MFS. Lack of association with other standard RA outcome measures suggests that relying on measures such as DAS28 alone may miss clinically important foot pathology. The picture was a useful complement to the questionnaire. This simple screening tool used regularly in clinic could aid early identification and treatment of RA foot and ankle problems.

Disclosure statement: The authors have declared no conflicts of interest.

References

148. A CONTROLLED PILOT ASSESSMENT OF THE UTILITY OF VISUAL FEEDBACK IN THE TREATMENT OF EARLY RHEUMATOID ARTHRITIS

Yasser El Miedany1,2, Maha El Gaafary3 and Deborah Palmer3
1Rheumatology, Darent Valley Hospital, Dartford, United Kingdom; 2Rheumatology and Rehabilitation, Ain Shams University, Cairo, Egypt; 3Community, Environmental and Occupational Medicine, Ain Shams University, Cairo, Egypt

Background: Visual feedback has contributed in the management of neuromuscular and psychiatric disorders, however, it has not yet been applied in rheumatology. Visual feedback is a relatively new tool that enables the patients to visualize and monitor a real-time change of their disease activity parameters as well as the patient’s reported outcome measures. Integrating electronic data recording in the standard rheumatology clinical practice made visual feedback possible in the treatment of patients with early inflammatory arthritis (EA) and how ubiquitous computing technology can improve the patients’ compliance and adherence to therapy.

Methods: This was a double-blind randomized controlled study, which included 111 patients diagnosed to have EA according to the new ACR/EULAR criteria. All patients received DMARDs therapy and were monitored over the period of 1-year. By the 6th month of treatment, the patients were randomly allocated to an active group (55 patients) to who the visual feedback (visualization of the charts showing the disease progression) was added to their management protocol, and a control group (56 patients) who continued their routine management. The patients were monitored for another 6-months period. All the patient’s disease activity parameters, patient reported outcome measures (PROMs), medications and co-morbidity scores were recorded using the EROMIA software [1]. Primary outcome was the patients’ adherence to their medications; change in disease activity score (DAS-28) and PROMs. Secondary outcome was the outcome of a questionnaire completed by every patient in both the active group and control group (using VAS) by the end of 1-year of management, to rate the patient’s perspective regarding their condition and treatment.

Results: The visual feedback provided a significant reduction of disease activity parameters as well as improvement of the patients’ adherence to anti-rheumatic therapy, allowing their DMARDs therapy to continue. The patients on the DMARDs therapy because of intolerance was significantly less in the active group. The improvement of disease activity parameters was associated with improvement in functional disability and quality of life scores. Mean changes in disease activity parameters showed that important differences at 3 and 6 months of therapy but differences were
statistically significant at 12 months follow up (p < 0.01). Medication compliance was significantly correlated with changes in all measured disease parameters.

Conclusions: By recording and monitoring disease activity electro-nically and introducing visual feedback therapy into clinical practice, a new experience can be created. Visual feedback enabled the patients to see how they are doing regarding their disease activity and helped to optimize their adherence to their treatment. Visual feedback had a protective and significant impact on the disease activity control.

Disclosure statement: The authors have declared no conflicts of interest.

Reference

149. SIX-YEAR OUTCOME OF EARLY ARTHRITIS CLINIC: IMPLEMENTATION OF THE MATRIX MODEL FOR THE PREDICTION OF RAPID RADIOGRAPHIC PROGRESSION AND COMMENCING BIOLOGIC THERAPY
Yasser El Miedany1, Maha El Gaafary2 and Deborah Palmer1
1Rheumatology, Darent Valley Hospital, Dartford, United Kingdom; 2Community, Environmental and Occupational Medicine, Ain Shams University, Cairo, Egypt

Background: The current paradigm for early arthritis suggests that the inflammatory process is at its peak in the first few years, leading to erosive joint damage and functional disability. Identifying patients with RA at high risk of rapid radiographic progression (RPP) is critical for making appropriate treatment decisions. The latest NICE guidelines (2009) supported the recent trend of early diagnosis and management of the condition. An early arthritis clinic has been set up at Darent Valley Hospital, Dartford, for the past 6 years. Aim: To assess the feasibility of implementing the visual matrix model, which would predict the 1-year risk of rapid radiographic progression, for individual patients diagnosed and managed in the early arthritis clinic. Also to assess the ability of the matrix model to identify patients who might need combination of DMARDs/commencing biologic therapy.

Methods: This was a case-control retrospective study. The matrix model was applied to 102 patients who were diagnosed to have RA according to the new ACR/EULAR criteria and treated according to NICE guidelines (2009) (Mean time to start biologic therapy was 6.4±0.52 months). The control group included 105 patients diagnosed to have early inflammatory arthritis in the period of 2005-2008 (Mean time to start biologic therapy was 14.3±1.8 months). The matrix model was applied at 0 time (before starting DMARDs therapy), 3, 6 and 12 months after starting treatment. Biologic therapy was commenced in group 1 by 6-months time of DMARDs therapy, whereas the patients in group 2 continued on DMARDs therapy for the whole of first year. Modified Sharp/van der Heijde score (SHS) was assessed for all patients by the end of the first year of treatment. Coordinates were illustrated to identify the best discriminating point that shows the highest sensitivity and the lowest 1-specificity (false positives) values.

Results:
1. There was no significant difference on comparing the baseline characteristics in both groups included in this work. By the end of 1-year of therapy, there was significant difference (p < 0.001) between the matrix score in both groups assessed (being significantly lower in group 1) supporting the favorable effect of the biologic over DMARDs therapy. Also, the matrix score correlated significantly with the SHS score. AUC and coordinate points showed that the sensitivity as well as specificity of the matrix score were highest at baseline, as well as at 6-months of therapy followed by 3 months of therapy.

Conclusions: The matrix models predicted the risk of RPP at 1-year using initiated treatment and easily accessible clinical and laboratory variables. The matrix model can be implemented in the early arthritis clinic to identify those patients at risk who should receive the combination of DMARDs therapy by 3-months or should start biologic therapy by 6-months of starting DMARDs therapy.

Disclosure statement: The authors have declared no conflicts of interest.

150. IN THE AGE OF BIOLOGIC THERAPY: WHICH ANTI-TNF AGENT IS SAFE TO USE IN PATIENTS WITH LATENT TUBERCULOSIS
Yasser El Miedany1 and Deborah Palmer1
1Rheumatology, Darent Valley Hospital, Dartford, United Kingdom

Background: The failure to screen for tuberculosis before the initiation of biologic therapy may result in adverse outcomes for both the patient and the overall health of the community. Similarly, reactivation of latent tuberculosis (patients infected with M. tuberculosis but does not have active tuberculosis disease) is a high risk in inflammatory arthritis patients treated with anti-TNF therapy, as this may lead to activation of the infection. Antigen-specific γ-IFN release assays such as T-SPOT have been evaluated in various populations and are reported to perform better than tuberculin skin testing in the diagnosis of TB infection (high specificity (93-99%)).

Aim: To assess the safety of the different anti-TNF agents in patients with latent tuberculosis and the impact of anti-tuberculosis therapy on the disease activity.

Methods: Upon referral for biologic therapy, all patients were assessed in the pre-biologic therapy assessment clinic. Assessment of tuberculosis infection risk includes history of specific symptoms (productive cough of stained sputum or TB travel risk factors for individual or close relatives), BCG scar, chest X-ray and T-spot test. 21 patients with latent TB were identified and treated with antituberculosis agent under care of the chest clinic for 3 months following which anti-TNF therapy was started. Patient choice approach was implemented, after explaining all pros and cons of different anti-TNF agents available. Patients were monitored 3 monthly for symptoms of active TB disease, disease activity and compliance to their medications. Chest X-ray was taken every 3 months. Primary outcome was the chest status at the end of the year and whether there has been flare up of the TB infection. Secondary outcome was the disease activity score at the end of the year.

Results: 8 patients received enbrel, 7 patients received humira whereas 6 patients received infliximab infusions. There was no significant difference on comparing, age, sex or disease activity parameters between the 3 groups (p > 0.05). Prior to therapy the chest X-ray did not show any active lung lesion in all patients presented with reactive T-spot test. At one year of anti-TNF therapy there was no activation of TB infection in any patient in the 3 groups. There was no significant difference between the 3 patients groups in terms of disease activity parameters (p > 0.05).

Conclusions: It is relatively safe to use any of the anti-TNF agents, enbrel, humira, or infliximab in patients with latent TB. Having a reactive T-spot test/ latent tuberculosis is not a contraindication to anti-TNF therapy. Using anti-tuberculosis therapy for 3 months after which the patient can start his anti-TNF therapy with 3 monthly X-ray chest seems a safe protocol for this group of patient.

Disclosure statement: The authors have declared no conflicts of interest.

151. SYSTEMATIC REVIEW AND META-ANALYSES OF NON-PHARMACOLOGICAL INTERVENTIONS FOR FATIGUE IN RHEUMATOID ARTHRITIS
Fiona Cramp1, Sarah Hewlett1,2, Celia Almeida1,2, John Kirwan3, Ernest Choy4, Trudie Chalder5, Jon Pollock6 and Robin Christensen6
1Department of Allied Health Professions, University of the West of England, Bristol, United Kingdom; 2Academic Rheumatology Unit, University of Bristol, Bristol Royal Infirmary, Bristol, United Kingdom; 3Section of Rheumatology, Cardiff University, Cardiff, United Kingdom; 4Department of Psychological Medicine, Institute of Psychiatry, King’s College London, London, United Kingdom; 5The Parker Institute: Musculoskeletal Statistics Unit (MSU), Copenhagen University Hospital at Frederiksberg, Copenhagen, Denmark

Background: Fatigue is a common and distressing symptom for patients with rheumatoid arthritis (RA) with no accepted evidence based management guidelines. Non-pharmacological interventions, such as physical activity and psychosocial interventions have been shown to help people with a range of other long term conditions manage subjective fatigue. The objective of this review was to evaluate the effectiveness and safety of non-pharmacological interventions for the management of fatigue in people with RA.

Methods: The following electronic databases were searched: Cochrane Central Register of Controlled Trials; Cochrane Database of Systematic Reviews; Current Controlled Trials Register; The National Research Register Archive; The UKCRN Portfolio Database; MEDLINE; EMBASE; AMED; CINAHL; PsyCINFO; Social Science Citation Index; Web of Science; Dissertation Abstracts International. In addition reference lists of articles identified for inclusion were checked for additional studies and key authors were contacted.

Randomised controlled trials were included if they evaluated a non-pharmacological intervention in people with RA, with self-reported fatigue as an outcome measure. Two reviewers selected relevant trials, assessed methodological quality and extracted data. The Standardized Mean Difference (SMD) was applied as the effect size.
Measure applicable across different outcome measures. Data were pooled using meta-analysis with a random-effects model with inconsistency evaluated based on the I-squared value.

Results: Of 54 studies initially identified, 19 met the inclusion criteria with a total of 2240 participants with RA. Included studies investigated physical activity interventions \( k=5 \), psychosocial interventions \( k=10 \), herbal medicine \( k=1 \), omega-3 fatty acid supplementation \( k=1 \), menopausal diet \( k=1 \) and the provision of Health Tracker information \( k=1 \). The risk of bias in the included studies varied from high (53%) to low (37%). No adverse effects were reported in any of the studies. Only three studies reported adverse events but there was no difference in incidence or severity between the intervention and control groups. At the end of the intervention period a non-significant trend in favour of physical activity was demonstrated for pre-post test mean change in self-reported fatigue (SMD -0.17, 95% CIs -0.53 to 0.18; I-sq = 46%). A non-significant trend in favour of psychosocial interventions was also demonstrated (SMD -0.14, 95% CIs -0.30 to 0.02, I-sq = 19%). The remaining four studies investigated diverse non-pharmacological interventions and were therefore not appropriate for combining within a meta-analysis.

Conclusions: This systematic review shows that there is currently insufficient evidence of the effectiveness of non-pharmacological interventions in the management of self-reported fatigue in RA. Those with fatigue and physical activity show some promise but require further investigation.

Disclosure statement: S.H. has received research grants from GlaxoSmithKline and Arthritis Research UK. All other authors have declared no conflicts of interest.

### 152. FACTORS ASSOCIATED WITH EXCESS Atherosclerotic Plaque in Early Inflammatory Polyarthritis: Results from the Norfolk Arthritis Register

Hoda Mirjafari, Suzanne Verstappen, Diane Bunn, Helena Edlin, Valentine Charlton-Mensy, Philip Pemberton, Tamya Marshall, Paddy Wilson, Mark Lunt, Deborah Symmons and Ian N. Bruce

1Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom; 2Rheumatology Department, Norfolk and Norwich University Hospitals, Norwich, United Kingdom; 3Department for Vascular Studies, Manchester Royal Infirmary, Manchester, United Kingdom; 4Cardiovascular Research Group, The University of Manchester, Manchester, United Kingdom; 5Biochemistry Laboratory, Manchester Royal Infirmary, Manchester, United Kingdom

**Background:** Patients with inflammatory polyarthritis (IP) have excess cardiovascular (CVD) mortality due to accelerated atherosclerosis. Identifying individuals with subclinical atheromatous plaque and markers associated with it may allow for targeted CVD risk management early in the disease course and is driven principally by traditional risk factors. We aimed to compare the prevalence of carotid markers associated with it in patients with IP and novel risk factors associated with plaque after age and gender adjustment. An additive stepwise multivariable regression model was developed to investigate independent associations with plaque.

**Methods:** Consecutive patients with early IP (≥ 2 joints swollen for ≥ 4 weeks) aged 18-65 years, who were within 24 months of symptom onset and recruited as part of a primary-care based inception cohort between 2004-2008. Patients were age and gender frequency matched with controls. At baseline, subjects had classic risk factors of CVD and RA. However of the GPs identifying this susceptibility only 40% performed any form of primary prevention risk assessment. 5.3% of GPs felt that CV risk management should occur in secondary care and 84% and 85% respectively reporting that a review article or presentation about cardiovascular risk in RA would be useful in their daily practice.

**Results:** Of the 292 patients and 67 controls studied 96 (29%) and 26 (33%) were male respectively. In the patients the median (IQR) age and symptom duration at study entry were 51 (42-58) years and 6.6 (4.2-11.2) months, 14 (4%) patients had prior CVD. Patients were more likely to smoke (75 [23%] vs 3 [4%] p < 0.05), be on antihypertensives (42 [13%] vs. 2 [2%] p < 0.05) and have previous steroid exposure (62 [19%] vs. 2 [3%] p < 0.05). Carotid plaque was more prevalent in patients than controls on baseline scans (151[46%] vs 16 [24%] OR [95% CI] 2.9 [1.6, 5.2]). In univariate analysis; age, smoking, BP, total cholesterol, LDL, triglyceride, hs-CRP, adiponectin and Apo B were significantly associated with plaque in patients. In an additive stepwise multiple regression model age, BP, Apo B, and adiponectin remained independent predictors of plaque (Table 1).

<table>
<thead>
<tr>
<th>Variable</th>
<th>IP Subjects Odds Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age when seen (per year)</td>
<td>1.10 (1.06, 1.14)</td>
</tr>
<tr>
<td>Apo B (per g/L)</td>
<td>211.47 (87.3, 5123.04)</td>
</tr>
<tr>
<td>Adiponectin (per mg/L)</td>
<td>1.17 (1.04, 1.31)</td>
</tr>
<tr>
<td>Systolic BP (per mmHg)</td>
<td>1.02 (1.00, 1.04)</td>
</tr>
</tbody>
</table>

### 153. The Recognition and Assessment of Cardiovascular Risk in People with Rheumatoid Arthritis in Primary Care: A Questionnaire-Based Study of General Practitioners

Carolyn Bell and Ian F. Rowe

1Rheumatology, Worcestershire Acute NHS Trust, Worcester, United Kingdom

**Background:** Rheumatoid arthritis (RA) is a chronic, inflammatory disease affecting approximately 1% of the adult population. Patients with RA are recognised as having increased cardiovascular morbidity and mortality. Within the UK the majority of cardiovascular risk assessment and management occurs within primary care. This study aimed to determine how well-received the association between RA and excess cardiovascular risk is within primary care and the current assessment strategies being employed by general practitioners (GPs).

**Methods:** Questionnaires were sent to all 376 GPs in the Worcestershire Primary Care Trust.

**Results:** Of the 207 GPs responding to the questionnaire 32% identified RA as an independent risk factor for cardiovascular (CV) disease, 15% and 34% respectively assessed their RA patients for primary and secondary prevention of their CV risks. Of those who made an assessment 18.4% of GPs adjusted the calculated risk derived from standard charts. The frequency of assessment was statistically significantly greater \( p < 0.0001 \) among those GPs who had received a form of education about the association between CV disease and RA. However, of the GPs identifying this susceptibility only 40% performed any form of primary prevention risk assessment. 5.3% of GPs felt that CV risk management should occur in secondary care with 84% and 85% respectively reporting that a review article or presentation about cardiovascular risk in RA would be useful in their daily practice.

**Conclusions:** At present the excess risk of CV disease conferred by RA is under-recognised and under-assessed in primary care. Currently educational resources on this topic targeted at GPs are lacking and may in part account for our findings. However, even when GPs did identify the risk of CV disease in RA or had received education about it, this did not consistently change their clinical management. Further work to promote knowledge and management strategies for CV disease in RA is therefore needed to improve the care of patients with this condition.

**Disclosure statement:** C.B. has received sponsorship to attend a conference from Roche. All other authors have declared no conflicts of interest.

### 154. Sustained Clinical Remission in RA: Prevalence and Prognostic Factors in an Inception Cohort of Patients Treated with Conventional DMARD Therapy

Keenanar Jayakumar, Sam J. Norton, Josh Dixey, Peter Williams and Adam Young

1Rheumatology, ERAIS, St Albans, United Kingdom; 2Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom

**Background:** Clinical remission is now a realistic goal in managing rheumatoid arthritis (RA) since the introduction of biologics. However, data on sustained clinical remission in conventionally treated RA is limited. This study examines prevalence/predictive factors of sustained clinical remission in patients treated with standard DMARD therapy.
therapy prior to the biologic era in an inception cohort over the first 5 years.

Methods: Consecutively newly diagnosed RA patients (~2 yrs from symptom onset and DMARD naïve) were recruited at presentation from 9 centres across England into an inception cohort (1986-1998) (n = 1460), and followed annually employing standard clinical, laboratory and radiological assessments. Disease activity was assessed using the original 3-variable DAS that uses swollen/tender joint counts, and acute phase response (ESR/CRP). Point remission (DAS at one point) was defined by DAS < 1.6 according to EULAR response criteria (DAS28<2.6). For this study, sustained clinical remission was defined by DAS < 3.2 at all 3, 4, and 5yr follow ups, non remission if DAS = 1.6-3.0 at all 3 follow ups, and partial remission for other combinations.

Results: Point remission based on DAS at 3, 4 and 5yrs was 25%, 26% and 22% respectively, but only 11% (n=78) had sustained DAS remission. Baseline predictors for sustained DAS remission using univariate analysis were men (OR 2.6, 95%CI 1.6-4.2), 6 or less months of symptoms prior to study entry (OR 1.6, 95%CI 1.0-2.7), <10 tender joints (OR 3.0, 95%CI 1.7-5.0), <13 swollen joints (OR 1.9, 95%CI 1.1-3.0), DAS < 4.1 (OR 2.7, 95%CI 1.6-4.6) and HAQ <1.0 (95%CI 1.3-3.6). Only men, symptom duration and tender joints remained independent predictors of sustained DAS remission in multivariate analysis. Patients with sustained DAS remission by 5yrs had better outcomes over time as assessed by less DMARD therapies, as well as radiographic progression and functional impairment. Mean HAQ decreased from 0.17-0.13 (p<0.001) in sustained DAS remission, compared to an increase from 0.92-1.1 (p<0.001) in the non-remission group.

Conclusions: In RA patients managed with conventional DMARDS, point remission rates were around 25%. 11% had sustained DAS remission by 5yrs with a positive impact on structural/functional outcomes. These results provide a benchmark for modern pharmacological approach to RA. Remission maintenance, not only induction should be the main therapeutic target.

Disclosure statement: The authors have declared no conflicts of interest.

155. THE SAFETY AND ACCEPTABILITY OF ULTRASOUND-GUIDED BIOPSY IN EARLY ARTHRITIS PATIENTS

Hariney Kurunadalingam1, Iram Parwaiz2, Kanta Kumar1, Kath Howlett1, Becki Hands2, Karim Raza3, Costantino Pitzalis4, Chris Buckley2, Stephen Kelly5 and Andrew Filer

Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom; 2Rheumatology Department, Barts and the Royal London, London, United Kingdom

Background: Current research strategies addressing prediction of outcome in early arthritis such as PEAC (the Pathobiology of Early Arthritis Cohort) and the Birmingham Very Early Arthritis Clinic rely upon the procurement of tissue from patients at the earliest stages of disease, necessitating safe, minimally invasive techniques which are acceptable to newly presenting arthritis patients. We assessed the safety and acceptability of ultrasound guided biopsy, a less invasive alternative to formal arthroscopy, used by centres in Birmingham and London.

Methods: Patients with treatment naive early synovitis of at least one joint, up to one year symptom duration, and at least one joint amenable to synovial biopsy gave written informed consent to be recruited from hospitals in London and Birmingham, representing the first cohort of patients in the UK upon whom these procedures were performed. The patients were assessed pre, intra and 2 weeks post biopsy on a standard proforma. Patient reported information on joint status and patient acceptability was recorded by likert scales, visual analogue scales (VAS) and free text entry in a confidential proforma.

Results: 123 participants were included (mean age 53 (19-83) years, M:F 53:70). Adverse events were compared with data for conventional arthroscopy. During biopsy arthralgia occurred in 24%, while minor complications of presyncope and syncope occurred below 3%, with no DVT, joint infection, thrombophlebitis or cardiovascular damage. The only significant complication was a wound infection, used as a disease control to inform further practice. A single, mild haemarthrosis occurred, giving a similar rate to major haemarthrosis seen with conventional arthroscopy (0.8% vs 0.9%). Patient acceptability of biopsy procedures was excellent. The majority (81%) of biopsies involved either minimal or no discomfort. Biopsies of small joints involved significantly less discomfort compared to large joints (p < 0.0001), but provided less tissue for analysis. Two weeks post procedure, most patients (98% Birmingham, 91% London) felt the biopsied joint was “the same” or “better”. Significantly more patients in Birmingham felt the joint was improved (p = 0.05), due to a higher number of very early patients with resolving arthritis. Corresponding improvements in VAS scores for pain, swelling and stiffness were seen. Crucially, most patients (81% in Birmingham and 72% in London) would be likely to consent for a repeat procedure.

Conclusions: Acknowledging a single early wound infection, the side effect profile of US guided biopsy matches or improves upon conventional arthroscopy with an excellent acceptability profile. Patients are happy to undergo repeat procedures (12 repeat biopsies in the Birmingham cohort to date). This novel technique has the potential to replace arthroscopy as a research and clinical trial procedure.

Disclosure statement: The authors have declared no conflicts of interest.

156. SUPPRESSION OF BONE TURNOVER BY B-CELL DEPLETION IN PATIENTS WITH RHEUMATOID ARTHRITIS

Gill Wheeler1, Vanessa E. Hogan1, YK Onno Teng2, Janineke Tekstra2, Stephen P. Tuck3, Floris P. Lathe4, Tom W. Hultzing5, Johannahs W. Biltsma5,2, Roger M. Francis2,

1Biochemistry, The James Cook University Hospital, Middlesbrough, United Kingdom; 2Musculoskeletal Research Group, Newcastle University, Newcastle upon Tyne, United Kingdom; 3Rheumatology, Leiden University Medical Centre, Leiden, Netherlands; 4Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, Netherlands; 5Rheumatology, The James Cook University Hospital, Middlesbrough, United Kingdom

Background: Recent investigations have provided abundant evidence for an intricate interaction between the immune and skeletal systems. Rheumatoid arthritis (RA) is the most prevalent inflammatory joint disease, in which B cells play an important role. The skeletal complications of RA consist of focal erosion of marginal and subchondral bone, juxta-articular osteoporosis and generalised bone loss with reduced bone mass. The role of B-cells in bone turnover is controversial and RA subjects treated with rituximab therapy provide an ideal model for determining the role of B cells in inflammatory bone resorption. This study was undertaken to investigate changes in biochemical markers of bone turnover before and after B cell depletion therapy in RA patients.

Methods: Serum from 46 patients with refractory RA, collected pre- and post-rituximab, was analysed for biomarkers of bone turnover (procollagen type 1 amino-terminal propeptide [PINP], osteocalcin, beta-isomerised carboxy terminal telopeptide of type I collagen [bCTx], osteoprotegerin [OPG]).

Results: A significant decrease in bone resorption was observed 6 months after rituximab (median change in bCTx -50 ng/L, 95%CI -8.136, p = 0.001), mirrored by a significant reduction in disease activity. There was a significant increase in PINP (median change 8.0 ug/L, 95%CI 1.0, 11.2, p = 0.02), a marker of bone formation, but no significant change in osteocalcin or OPG levels. The percentage change from baseline of bCTx in a subgroup of patients (not on prednisolone or a bisphosphonate) was significantly correlated with the percentage reduction in DAS28 score (r=0.570, p = 0.014).

Conclusions: B-cell depletion with rituximab in RA results in a significant suppression in bone resorption accompanied by an increase in bone formation. This may be a direct effect on osteoblasts and osteoclasts respectively, and be at least partially explained by the decreased inflammation and disease activity.

Disclosure statement: J.B. and J.V. have received consultancy and speaker fees and research grants from Roche. T.H. has received lecture/consultancy fees from Schering-Plough, Bristol-Myers Squibb, Biotest AG, Wyeth/Pfizer, Novartis, Roche, Sanofi-Aventis, Abbott and Axis-Shield diagnostics, and support for traveling to EULAR/ACR meetings from Roche and Abbott. S.T. has received speaker fees from Eli Lilly. All other authors have declared no conflicts of interest.
158. DELAYS IN ASSESSMENT OF PATIENTS WITH NEW ONSET RHEUMATOID ARTHRITIS: VARIATIONS AROUND EUROPE

Karim Raza1, Kanta Kumar2, Rebecca Stack1, Brygidka Kwiatkowska3, Sobibett Rantapaa-Dahquist4, Tore Saxne5, Prodrromos Sidipoulos6, Elena Ktenadakis6, Chariklia Misiraki6, Herman Mann6, Jiri Vencovsky7, Adrian Ciurea8, Giorgio Tamborrini9, Diego Kyburz10, Hans Bastian10, Gerd R. Burmeister11, Jacqueline Defet6 and Christopher D. Buckley12

1Immunity and Infection, University of Birmingham, Birmingham, United Kingdom; 2Rheumatology, Institute of Rheumatology, Warsaw, Poland; 3Department of Rheumatology, University Hospital, Umea, Sweden; 4Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden; 5University of Crete, University of Crete, Crete, Greece; 6Institute of Rheumatology, Charles University, Prague, Czech Republic; 7Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland; 8Department of Rheumatology and Clinical Immunology, Charité, Berlin, Germany

Background: The first 3 to 4 months after symptom onset represent an important therapeutic window in RA. Delays in assessment by rheumatologists, and consequently in DMARD initiation, reflect a composite of 4 time intervals: [1] Onset of symptoms to request to see health care professional (HCP); [2] Request to see HCP to assessment by HCP; [3] Initial assessment by HCP to referral to rheumatologist; [4] Referral to rheumatologist to assessment by rheumatologist. In previous work from the UK, the median delay from symptom onset to rheumatology assessment was over 20 weeks. We sought to quantify delays in assessment of RA patients across Europe and to identify the principal reasons for delay in different countries.

Methods: Data (the 4 levels of delay listed above, age, gender and the initial HCP of contact) were collected from consecutively presenting RA patients fulfilling 1987 ACR criteria at initial assessment in Birmingham, Umea, Lund, Berlin, Warsaw, Prague, Zurich and Crete.

Results: Details of patients are shown (Table 1). The median delay from onset of inflammatory joint symptoms to assessment by a rheumatologist ranged from 20 to 38 weeks. The relative contributions of each level of delay to the total delay varied between units. In Birmingham and Crete, the greatest contribution was delay on the part of the patient in consulting a HCP. In Umea, Lund, Prague and Zurich, delay on the part of the patient in consulting a HCP, and delay on the part of the HCP in referring to a rheumatologist were equivalent contributors to overall delay. In Berlin and Warsaw, delay on the part of the patient in seeking medical advice was relatively short, with other components accounting for the majority of the overall delay.

Conclusions: Across Europe, delays in the assessment of RA patients by rheumatologists are too long. Tackling this should represent an important priority for strategies to improve RA outcomes. This study highlights the levels of delay that need to be targeted in individual countries.

### Table 1

<table>
<thead>
<tr>
<th>Country</th>
<th>Birmingham</th>
<th>Umea</th>
<th>Lund</th>
<th>Berlin</th>
<th>Warsaw</th>
<th>Prague</th>
<th>Zurich</th>
<th>Crete</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>50</td>
<td>50</td>
<td>48</td>
<td>50</td>
<td>55</td>
<td>50</td>
<td>49</td>
<td>42</td>
</tr>
<tr>
<td>Age, median (IQR), years</td>
<td>55 (44-69)</td>
<td>55 (42-67)</td>
<td>58 (45-68)</td>
<td>44 (35-59)</td>
<td>55 (47-62)</td>
<td>56 (40-62)</td>
<td>53 (36-62)</td>
<td>53 (43-62)</td>
</tr>
<tr>
<td>Gender: female, number (%)</td>
<td>33 (66)</td>
<td>36 (72)</td>
<td>35 (73)</td>
<td>35 (70)</td>
<td>41 (82)</td>
<td>35 (70)</td>
<td>37 (76)</td>
<td>36 (86)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Initial health care professional (HCP) of contact</th>
<th>GP</th>
<th>Rheumatologist</th>
<th>Intern</th>
<th>Company health service</th>
<th>Orthopaedic surgeon</th>
<th>Emergency department</th>
<th>Neurologist</th>
<th>Not recorded / other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birmingham</td>
<td>49</td>
<td>47</td>
<td>46</td>
<td>26</td>
<td>36</td>
<td>35</td>
<td>46</td>
<td>2</td>
</tr>
<tr>
<td>Umea</td>
<td>50</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>7</td>
<td>4</td>
<td>0</td>
<td>12</td>
</tr>
<tr>
<td>Lund</td>
<td>48</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td>Berlin</td>
<td>50</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td>Warsaw</td>
<td>50</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td>Prague</td>
<td>49</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td>Zurich</td>
<td>42</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td>Crete</td>
<td>36 (66)</td>
<td>36 (72)</td>
<td>35 (73)</td>
<td>35 (70)</td>
<td>41 (82)</td>
<td>35 (70)</td>
<td>37 (76)</td>
<td>36 (86)</td>
</tr>
</tbody>
</table>

| Delay 1: Patient delay in seeking appointment with initial HCP, median (IQR), weeks | 1 (1-3) | 1 (1-3) | 2 (1-2) | 2 (1-4) | 2 (1-4) | <1 (1-2) | 1 (1-2) | 12 (6-63) |
| Delay 2: Delay in assessment by initial HCP once decided to seek advice made, median (IQR), weeks | 2 (1-5) | 8 (2-20) | 8 (4-12) | 10 (2-33) | 12 (2-48) | 10 (3-52) | 8 (4-15) | 3 (0-4) |
| Delay 4: Rheumatologist delay in seeing patient once referred, median (IQR), weeks | 4 (2-6) | 4 (2-5) | 3 (2-4) | 11 (4-14) | 4 (1-8) | 4 (2-8) | 2 (1-3) | 4 (0-8) |
| Total delay from symptom onset to assessment by Rheumatologist, median (IQR), weeks | 21 (13-63) | 25 (14-53) | 22 (15-32) | 27 (19-43) | 35 (14-74) | 25 (12-77) | 20 (13-63) | 38 (16-192) |

*P value across levels of delay 1-4*<br>0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001

*Kruskal Wallis test comparing across levels of delay 1-4.
Disclosure statement: K.R. has received support from the European Union’s Sixth Framework Programme (AutoCure). All other authors have declared no conflicts of interest.

159. DAS28 USING CRP IS SIGNIFICANTLY LOWER THAN DAS28 ESR IN RA PATIENTS

Claire Sheehy1, Alexa Shipman1, Irina Stech1 and Chetan Mukhtyar2
1Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom

Background: The disease assessment score 28 joint count (DAS28) is a validated tool to assess disease activity in rheumatoid arthritis (RA) and is widely used in clinical trials. The original DAS28 has four components: tender joint count, swollen joint count, visual analogue score (VAS) of the patient’s global health and erythrocyte sedimentation rate (ESR). Versions of DAS28 which substitute C-reactive protein (CRP) instead of the ESR have been developed because CRP is not affected by age, gender and globulin levels. A three variable DAS28 without the VAS is also available. A DAS28 ≤2.6 has been proposed as remission and >5.1 as high disease activity. It is recognised that the DAS28 CRP values tend to be lower than the DAS28 ESR values but the quantum of difference is unknown. We aimed to quantify the difference and find the equivalent values for ‘remission’ and ‘high disease activity’ in the versions using the CRP.

Methods: Consecutive outpatient patients from general rheumatology and biologicics clinic were reviewed. Data collected included swollen joint count, tender joint, global health assessment, ESR and CRP. If any of these variables was not described, or the inflammatory markers had not been measured, then the letter was disregarded. Four versions of the DAS28 score were then calculated i.e. the DAS28 ESR 4 variables (4V), DAS28 CRP 4V, DAS28 ESR 3 variables (3V) and DAS28 CRP 3V. Statistical analysis was performed using SPSS 17.0 descriptive statistics, paired t-tests, and Spearman’s rank correlation tests were applied as appropriate. Receiver operating characteristic (ROC) curves were then constructed to find corresponding values of DAS28 CRP 4V, DAS28 CRP 4V and DAS28 ESR3V, for DAS28 CRP 4V values of 2.6 and 5.1.

Results: 986 patients with RA were analysed. The mean DAS28 CRP 4V of 3.59 differed significantly from the mean DAS28 CRP 4V of 3.00 (p < 0.001), DAS28 CRP 3V of 3.15 (p < 0.001), and DAS28 ESR 3V of 3.80 (p < 0.001). All 4 versions of the DAS28 were shown to be significantly correlated (using Spearman’s correlation) with each other, p < 0.001 for all comparisons. Values corresponding to DAS28 CRP 4V values of 2.6 and 5.1 are as in Table 1.

Conclusions: There is a strong correlation between all 4 versions of the DAS28, but the versions using CRP have statistically significant and clinically meaningful lower values. This should be borne in mind at a time that we are being encouraged to treat all of our patients DAS targets, as the inflammatory marker used will have significant impact on the ultimate DAS score.

Disclosure statement: The authors have declared no conflicts of interest.

Table 1

<table>
<thead>
<tr>
<th>DAS28 CRP 4V Value</th>
<th>Sens</th>
<th>Spec</th>
<th>DAS28 CRP 3V Value</th>
<th>Sens</th>
<th>Spec</th>
<th>DAS28 ESR 3V Value</th>
<th>Sens</th>
<th>Spec</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.6</td>
<td>1.89</td>
<td>88.1%</td>
<td>87.0%</td>
<td>2.150</td>
<td>88.1%</td>
<td>87.8%</td>
<td>2.98</td>
<td>97.0%</td>
</tr>
</tbody>
</table>

Sens: sensitivity; Spec: specificity

160. PRECLINICAL ATHEROSCLEROSIS IN RHEUMATOID ARTHRITIS: FROM ENDOTHELIAL DYSFUNCTION TO ATHEROSCLEROSIS

Fabiola Atzeni1, Simona Siti2, Livio Tomasoni2, Luigi Gianturco2, Cristian Ricci2, Piercarlo Sarzi-Puttini1, Vito De Gennaro Colonna3 and Maurizio Turzi4
1L.Sacco University Hospital, Rheumatology Unit, Milan, Italy; 2Dep. of Health Technologies, University of Milan, Cardiology Unit, IRCCS Galeazzi Orthopedic Institute, Milan, Italy; 3University of Milan and Clinical Epidemiology and Biometry Unit, IRCCS Policlinico San Donato, Milan, Institute of Medical Statistics and Biometry, O.L.M.” Faculty of Medicine, Milan, Italy; 4Pharmacology Department, University of Milan, Milan, Italy

Background: Rheumatoid arthritis (RA) is characterized by an increase in cardiovascular (CV) mortality compared to the general population. Endothelial dysfunction begins early after the onset of the disease and plays a pathogenetic role in the development of accelerated atherosclerosis. An impaired coronary flow reserve (CFR<2.5) has been proved to detect an early impairment of coronary microcirculation before the onset of clinical evidence of CV disease. Our objective was to evaluate the relationship between CFR, common carotid intima-media thickness (IMT) and asymmetric dimethylarginine (ADMA) in RA patients.

Methods: 120 adult patients with RA who fulfilled the ACR classification criteria [M 20 (15.6%), F 100 (83.4%)], mean age 61±13 years without clinical evidence of CV disease underwent standard echo-cardiography and dipyridamole stress echo was performed to evaluate CFR in the left descending coronary artery. Carotid ultrasound was performed to evaluate common carotid IMT and a blood sample was collected to measure plasma ADMA levels.

Results: 72/120 patients (60%) had CFR<2.5 of which 14/120 (12%) had CFR<2. All patients had normal wall motion at rest and during stress. Common carotid IMT was in normal range (0.73±0.13 mm) while plasma ADMA levels were increased (0.72±0.10). Linear regression analysis showed a significant negative correlation between CFR and common carotid IMT (P<0.001), plasma ADMA levels (P<0.001) and patient’s age (P=0.019). Moreover, CFR resulted negatively related with rheumatoid factor levels (P=0.009) and visual analogue score (VAS) (P=0.0092).

Conclusions: RA patients without clinical evidence of CV diseases showed an early impairment of coronary microcirculation and endothelial dysfunction before structural changes of large vessels occur. This suggests that reduced CFR is an early marker of enhanced atherosclerosis in a preclinical stage and it is associated with endothelial dysfunction. Moreover, indexes of disease activity resulted negatively associated with coronary microcirculation function

Disclosure statement: The authors have declared no conflicts of interest.

161. RARE AND OPPORTUNISTIC INFECTIONS IN PATIENTS EXPOSED TO ANTI-TNF THERAPY: RESULTS FROM THE BSR BILOGICS REGISTER (BSRBR)

James Galloway1, Audrey Low1, Louise K. Mercer1, Will Dixon1, Andrew Ustianowski2, Kath Watson1, Mark Lunt1 and the BSRBR Dep.
1Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom; 2Department of Infectious Diseases, North Manchester General Hospital, Manchester, United Kingdom

Table 1: Baseline characteristics and incidence of infections

<table>
<thead>
<tr>
<th>Infections</th>
<th>DMARD</th>
<th>All-anti-TNF</th>
<th>ETN</th>
<th>INF</th>
<th>ADA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects, n</td>
<td>3666</td>
<td>11864</td>
<td>4136</td>
<td>3472</td>
<td>4256</td>
</tr>
<tr>
<td>Mean age (y.o.), years</td>
<td>60 (12)</td>
<td>56 (12)</td>
<td>56 (12)</td>
<td>57 (12)</td>
<td>57 (12)</td>
</tr>
<tr>
<td>Female gender, n (%)</td>
<td>2648 (72)</td>
<td>9038 (76)</td>
<td>3190 (77)</td>
<td>2624 (76)</td>
<td>3224 (76)</td>
</tr>
<tr>
<td>Disease Duration, median (y.o.), years</td>
<td>6 (1-15)</td>
<td>11 (6-19)</td>
<td>12 (6-19)</td>
<td>12 (6-19)</td>
<td>10 (5-18)</td>
</tr>
<tr>
<td>Baseline used n (%)</td>
<td>80 (23)</td>
<td>524 (43)</td>
<td>1977 (48)</td>
<td>1609 (46)</td>
<td>1657 (49)</td>
</tr>
<tr>
<td>Baseline, n (%) 5.1 (1.3)</td>
<td>6.6 (1.0)</td>
<td>6.6 (1.0)</td>
<td>6.6 (1.0)</td>
<td>6.5 (1.0)</td>
<td></td>
</tr>
<tr>
<td>Exposure, yrs</td>
<td>12592</td>
<td>53715</td>
<td>23026</td>
<td>13476</td>
<td>17211</td>
</tr>
<tr>
<td>All rare / opportunistic infections: n</td>
<td>53</td>
<td>18</td>
<td>21</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Incidence rate /10000 pyrs (95% confidence interval)</td>
<td>4.0 (1.3, 9.3)</td>
<td>10.0 (7.4, 12.9)</td>
<td>7.8 (4.6, 12.4)</td>
<td>15.6 (9.6, 23.8)</td>
<td>8.1 (4.4, 13.6)</td>
</tr>
<tr>
<td>Bacterial endocarditis: n</td>
<td>1</td>
<td>13</td>
<td>6</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Invasive infection: n</td>
<td>1</td>
<td>4</td>
<td>1</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Legionellosis: n</td>
<td>0</td>
<td>6</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Listeriosis: n</td>
<td>1</td>
<td>8</td>
<td>2</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Multidrug-resistant: n</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Pneumocystis pneumonia: n</td>
<td>1</td>
<td>7</td>
<td>2</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Invasive salmonellosis: n</td>
<td>1</td>
<td>7</td>
<td>4</td>
<td>3</td>
<td>0</td>
</tr>
</tbody>
</table>
Background: Anti-TNF therapy is associated with a small increased risk of infection. There are biological reasons to expect that certain infections might be disproportionally increased, especially those caused by intracellular pathogens.

Methods: The BSRBR was established in 2001 to evaluate the safety of anti-TNF therapies etanercept (ETN), infliximab (INF) and adalimumab (ADA) in patients with RA. The anti-TNF treated cohort was recruited alongside a comparator group with active disease (DAS28 >4.2) treated with DMARDs. Patients were recruited between 01/10/2001 and 30/06/2008 and followed up by consultant and patient questionnaires until 31/12/2009 or death, whichever came first. The BSRBR defined a list of opportunistic infections at its outset. In addition to these, we included infective endocarditis. Tuberculosis was excluded from this analysis as we have reported on this previously.

Results: 11 864 anti-TNF and 3666 DMARD patients were included (Table 1). 58 rare or opportunistic infections were identified during the follow up (Anti-TNF 53; DMARD 5). The absolute rates of these infections were low in both cohorts (anti-TNF 10/10000 patient years follow up (pyrs); DMARD 4/10000 pyrs). Within the anti-TNF cohort, endocarditis was the most frequent event (13/53). The other reported opportunistic infections in the anti-TNF cohort were: invasive fungal infection (2 aspergillus, 2 candida), legionellosis (6), legionariosis (8), multidemarterial shingles (8), pneumocystis pneumonia (7), and invasive salmosellosis (7). These events were distributed amongst patients on each of the 3 anti-TNF agents.

Conclusions: The crude rate of rare or opportunistic infections and in particular endocarditis, was higher in anti-TNF exposed patients. We cannot deduce whether this is directly attributable to the anti-TNF therapy itself or other confounders, such as concurrent corticosteroid exposure. The clinician managing a sick patient on anti-TNF therapy should be aware of this spectrum of infection.

Funding: The BSRBR is supported by a research grant from the British Society for Rheumatology.

Disclosure statement: The authors have declared no conflicts of interest.

162. FINE SPECIFICITY OF ANTI-CITRULLINATED PEPTIDE ANTIBODIES IS ASSOCIATED WITH RESPONSE TO ANTI-TNF AGENTS IN RHEUMATOID ARTHRITIS: RESULTS FROM THE BRITISH SOCIETY OF RHEUMATOLOGY BIOLOGICS REGISTER

Benjamin Fisher1, Darren Plant2, Karin Lundberg3, Peter J. Charles1, Anne Barton1 and Patrick Venables1
1Kennedy Institute of Rheumatology, Imperial College London, London, United Kingdom; 2Arthritis Research UK Epidemiology Unit, University of Manchester, London, United Kingdom; 3Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden

Background: Anti-CCP antibodies have been associated with a poor response to anti-TNF agents in RA. However, CCP is an autoreagent but a group of synthetic peptides designed to maximise diagnostic sensitivity and which may fail to differentiate important disease subsets. We examined whether antibodies to immunodominate nant epitopes from three candidate citrullinated autoantigens could further define a subset of RA patients with a poor response to anti-TNF.

Methods: Samples from 450 patients enrolled in the British Society of Rheumatology Biologics Register were analysed for antibodies to CCP2 and to peptides from citrullinated α-enolase (CEP-1), vimentin (cVim) and fibrinogen (cFib). Associations with change in DAS28 scores at 6 months were analysed by linear regression, and with EULAR response criteria by ordinal logistic regression.

Results: Anti-CEP-1, anti-cVim, anti-cFib and anti-CCP antibodies were present in 39%, 42%, 75% and 84% respectively. Anti-cFib antibodies were associated with a poorer response to anti-TNF therapy at 6 months using linear regression adjusted for baseline characteristics, and with a trend towards lower EULAR response. The subset with antibodies to both anti-CCP and anti-cFib antibodies had a worse outcome (linear regression coefficient for DAS28 score at 6 months 0.55; 95% CI 0.13, 0.97; p = 0.01) than the anti-cFib-/CEP-CCP subset (coefficient 0.31; 95% CI -0.24, 0.87; p = 0.27) when compared to those negative for both antibodies. The presence of anti-CEP-1 and anti-cVim antibodies was not associated with a poorer response.

Conclusion: The association of anti-cFib antibodies with a poorer response to anti-TNF therapy justifies further investigation of antibodies to specific citrullinated antigens as predictors of clinical outcomes in RA.

Disclosure statement: K.L. and P.V. own a patent on the use of CEP-1 peptide. All other authors have declared no conflicts of interest.

Jörgen’s syndrome and other connective tissue disorders

164. POTENTIALLY TREATABLE SYMPTOMS IN PRIMARY SJOGREN’S SYNDROME-ASSOCIATED FATIGUE

Julia Newton1, Danielle Powell1,2, Sheryl Mitchell1,3, Bridget Griffiths3, Simon Bowman3, Wan-Fai Ng3,4 and UK primary Sjögren’s syndrome Registry
1Institute of Ageing and Health, Newcastle University, Newcastle upon Tyne, United Kingdom; 2Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; 3Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; 4Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom